Russia advances development of cancer vaccines with early clinical use underway

Russia has announced significant progress in the development of vaccines targeting cancer and autoimmune diseases, with early clinical use already underway and broader applications under consideration, reports Prensa Latina, a partner of TV BRICS.

President of the Russian Academy of Sciences Gennady Krasnikov stated that national researchers are actively working on innovative vaccine technologies, particularly in oncology and immunology. He emphasised that the scientific potential in this field is considerable, although further progress will depend largely on sustained funding.

Earlier, the Ministry of Health of Russia confirmed the first use of a personalised mRNA vaccine for the treatment of melanoma in a patient. The case marks an important step in the practical application of advanced therapies tailored to individual patients, experts believe.

According to the Chief oncologist of the Ministry of Health and academician Andrey Kaprin, the use of mRNA-based treatments could expand beyond melanoma if current results prove successful. Researchers are closely monitoring outcomes to assess the broader clinical potential of this approach.

Government officials have also indicated that several cancer vaccines are in the process of registration, with plans to integrate them into the national compulsory health insurance system if trials confirm their safety and efficacy.

Experts underline that advances in vaccine technology may significantly strengthen the country’s position in global biomedical research, particularly in the rapidly evolving field of personalised medicine.